The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) have announced a positive opinion for the granting of a marketing authorisation for… Read More »EMA (European Medicines Agency) approves authorisation of ocular formulation of bevacizumab AMD.
Researchers at the Moorfields Eye Hospital and UCL Institute of Ophthalmology, University College London, UK, have reported the natural history of a retinopathy associated with… Read More »Natural history and characteristics of IQCB1(NPHP5) retinopathy may aim to measure relevant subsequent research outcomes.
Dear EURETINA Members, A very warm welcome to the April 12th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »April 12th, 2024 “EURETINA-Brief”© Issue No. 289
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced results from a new meta-analyses proposing that those treated with LUMEVOQ… Read More »GenSight Biologics announces initial results from a new meta-analyses of LUMEVOQ versus idebenone and natural history in ND4-LHON.
Researchers at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, has reported that an estimate cohort of one-third of inherited retinal dystrophy (IRD) patients had… Read More »A prospective cohort study of IRD patients report the frequency and distributions of ophthalmic surgical procedures at the Wilmer Eye Institute.
Researchers at the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, has reported an artificial intelligence (AI) tool, as a “large… Read More »AI responses (“chatbots”) compare favourably against ophthalmic specialists (human) using a “large language model” [LLM] for retinal and glaucoma diseases.
Dear EURETINA Members, A very warm welcome to the March 25th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »March 25th, 2024 “EURETINA-Brief”© Issue No. 288
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced positive clinical study update of a Phase 1/2 study of “OCU400”, a… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced positive clinical study update of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA).
Researchers at Newcastle University and Sunderland Eye Infirmary, UK, have reported that, to date, there is “no evidence that complement inhibition with any agent improves… Read More »A systematic review on complement inhibitors suggests no evidence to date from functional endpoints in advanced AMD.
Researchers at the Department of Ophthalmology, at The Hebrew University of Jerusalem, have reported a new comprehensive analysis on Best disease patients, aimed to document… Read More »Mutations, analysis and genotype-phenotype results from the largest cohort of Best disease patients in the Israeli population and worldwide.
